Morgan Stanley downgraded Fulcrum Therapeutics to Equal Weight from Overweight with a price target of $8, down from $27.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics price target lowered to $20 from $26 at Oppenheimer
- Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
- Fulcrum clinical hold ‘gut punch for shares,’ says Oppenheimer
- Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
- Fulcrum Therapeutics announces clinical hold on FTX-6058 in SCD